Huang Mingyao, Ji Quansong, Huang Huiyan, Wang Xiaoqian, Wang Lin
School of Basic Medicine, Putian University, Putian, Fujian, China.
Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fuzhou, Fujian, China.
Gut Microbes. 2025 Dec;17(1):2486519. doi: 10.1080/19490976.2025.2486519. Epub 2025 Apr 1.
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, with limited treatment options at advanced stages. The gut microbiota, a diverse community of microorganisms residing in the gastrointestinal tract, plays a pivotal role in regulating immune responses through the gut-liver axis. Emerging evidence underscores its impact on HCC progression and the efficacy of immunotherapy. This review explores the intricate interactions between gut microbiota and the immune system in HCC, with a focus on key immune cells and pathways involved in tumor immunity. Additionally, it highlights strategies for modulating the gut microbiota - such as fecal microbiota transplantation, dietary interventions, and probiotics - as potential approaches to enhancing immunotherapy outcomes. A deeper understanding of these mechanisms could pave the way for novel therapeutic strategies aimed at improving patient prognosis.
肝细胞癌(HCC)仍然是癌症相关死亡的主要原因,晚期治疗选择有限。肠道微生物群是存在于胃肠道中的多种微生物群落,通过肠-肝轴在调节免疫反应中起关键作用。新出现的证据强调了其对HCC进展和免疫治疗疗效的影响。本综述探讨了HCC中肠道微生物群与免疫系统之间的复杂相互作用,重点关注参与肿瘤免疫的关键免疫细胞和途径。此外,它还强调了调节肠道微生物群的策略——如粪便微生物群移植、饮食干预和益生菌——作为增强免疫治疗效果的潜在方法。对这些机制的更深入理解可能为旨在改善患者预后的新治疗策略铺平道路。